Cumberland Pharmaceuticals Inc., a U.S. specialty pharmaceutical company and Clinigen Group, the global pharmaceutical and services company, announce a new publication in Lung Cancer: Targets and Therapy of a contemporary retrospective series showing that subcutaneous amifostine administered before radiotherapy postponed the onset of acute esophagitis in stage III small cell lung cancer patients treated with concomitant doublet chemotherapy and hyperfractionated radiotherapy.
With major leadership changes, grant disruptions and terminations, and a stoked distrust in science, Steven Artandi, the director of Stanford Cancer Center, worries that young investigators will feel disenchanted by the U.S. research atmosphere and take their work and study elsewhere.
